Photodynamic therapy for skin field cancerization: An international consensus. International Society for Photodynamic Therapy in Dermatology

Journal of the European Academy of Dermatology and Venereology

Volumn 26, Issue 9, 2012, Pages 1063-1066

  Braathen, L R ^a   Morton, C A ^b   Basset Seguin, N ^c   Bissonnette, R ^d   Gerritsen, M J P ^e   Gilaberte, Y ^f   Calzavara Pinton, P ^g   Sidoroff, A ^h   Wulf, H C ⁱ   Szeimies, R M ^j  

^a Dermatology   (Switzerland)

^b Stirling Royal Infirmary   (United Kingdom)

^c SAINT LOUIS HOSPITAL   (France)

^d INNOVADERM RESEARCH   (Canada)

^e RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^f HOSPITAL SAN JORGE   (Spain)

^g SPEDALI CIVILI   (Italy)

^h INNSBRUCK MEDICAL UNIVERSITY   (Austria)

ⁱ BISPEBJERG HOSPITAL   (Denmark)

^j Klinikum Vest Academic Teaching Hospital   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER;

CANCER PREVENTION; HUMAN; MEDICAL SOCIETY; NON MELANOMA SKIN CANCER; NONHUMAN; PATIENT INFORMATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SKIN CARCINOGENESIS; TOPICAL TREATMENT;

HUMANS; PHOTOCHEMOTHERAPY; SKIN NEOPLASMS;

EID: 84865091893     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2011.04432.x     Document Type: Review

References (31)

1. Slaughter DP, Southwick HW, Smejkal W,. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953; 6: 963-968.
2. Slaughter DP,. The multiplicity of origin of malignant tumors; collective review. Internat Abstr Surg 1944; 79: 89-98.
3. Slaughter DP,. Multicentric origin of intraoral carcinoma. Surgery 1946; 20: 133-146.
4. Nindl I, Gottschling M, Krawtchenko N, et al. Low prevalence of p53, p16(INK4a) and Ha-ras tumour-specific mutations in low-graded actinic keratosis. Br J Dermatol 2007; 156 (Suppl 3): 34-39.
5. Jiang W, Ananthaswamy HN, Muller HK, Kripke ML,. p53 protects against skin cancer induction by UV-B radiation. Oncogene 1999; 18: 4247-4253.
6. Brash DE, Ziegler A, Jonason AS, Simon JA, Kunala S, Leffell DJ,. Sunlight and sunburn in human skin cancer: p53, apoptosis, and tumor promotion. J Investig Dermatol Symp Proc 1996; 1: 136-142.
7. Kramata P, Lu YP, Lou YR, Singh RN, Kwon SM, Conney AH,. Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB Irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. Cancer Res 2005; 65: 3577-3585.
8. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773-776.
9. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. Cancer Lett 1994; 85: 23-29.
10. Campbell C, Quinn AG, Ro YS, Angus B, Rees JL,. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. J Invest Dermatol 1993; 100: 746-748.
11. Nomura T, Nakajima H, Hongyo T, et al. Induction of cancer, actinic keratosis, and specific p53 mutations by UVB light in human skin maintained in severe combined immunodeficient mice. Cancer Res 1997; 57: 2081-2084.
12. Einspahr JG, Alberts DS, Warneke JA, et al. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999; 1: 468-475.
13. Mudgil AV, Segal N, Andriani F, Wang Y, Fusenig NE, Garlick JA,. Ultraviolet B irradiation induces expansion of intraepithelial tumor cells in a tissue model of early cancer progression. J Invest Dermatol 2003; 121: 191-197.
14. de Gruijl FR,. p53 mutations as a marker of skin cancer risk: comparison of UVA and UVB effects. Exp Dermatol 2002; 11 (Suppl 1): 37-39.
15. Ananthaswamy HN, Loughlin SM, Ullrich SE, Kripke ML,. Inhibition of UV-induced p53 mutations by sunscreens: implications for skin cancer prevention. J Investig Dermatol Symp Proc 1998; 3: 52-56.
16. Madan V, Lear JT, Szeimies RM,. Non-melanoma skin cancer. Lancet 2010; 375: 673-685.
17. Ramsay HM, Fryer AA, Reece S, Smith AG, Harden PN,. Clinical risk factors associated with non-melanoma skin cancer in renal transplant recipients. Am J Kidney Dis 2000; 36: 167-176.
18. Babilas P, Schreml S, Landthaler M, Szeimies RM,. Photodynamic therapy in dermatology: state-of-the-art. Photodermatol Photoimmunol Photomed 2010; 26: 118-132.
19. Sidoroff A, Thaler P,. Taking treatment decisions in non-melanoma skin cancer-the place for topical photodynamic therapy (PDT). Photodiagnosis Photodyn Ther 2010; 7: 24-32.
20. Braathen LR, Szeimies RM, Basset-Seguin N, et al. Guidelines on the use of photodynamic therapy for non-melanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. J Am Acad Dermatol 2007; 56: 125-143.
21. Christensen E, Warloe T, Kroon S, et al. Norwegian Photodynamic Therapy (PDT) Group. Guidelines for practical use of MAL-PDT in non-melanoma skin cancer. J Eur Acad Dermatol Venereol 2010; 24: 505-512.
22. Morton CA, McKenna KE, Rhodes LE,. British Association of Dermatologists Therapy Guidelines and Audit Subcommittee and the British Photodermatology Group. Guidelines for topical photodynamic therapy: update. Br J Dermatol 2008; 159: 1245-1266.
23. Kleinpenning MM, Van de Kerkhof PC, Gerritsen RM,. The clinical efficacy of topical methyl-aminolevulinate photodynamic therapy in moderate to severe actinic keratoses of the face and scalp. J Dermatolog Treat 2010; 21: 252-257.
24. Stender IM, Bech-Thomsen N, Poulsen T, Wulf HC,. Photodynamic therapy with topical delta-aminolevulinic acid delays UV photocarcinogenesis in hairless mice. Photochem Photobiol 1997; 66: 493-496.
25. Sharfaei S, Juzenas P, Moan J, Bissonnette R,. Weekly topical application of methyl aminolevulinate followed by light exposure delays the appearance of UV-induced skin tumors in mice. Arch Dermatol Res 2002; 294: 237-242.
26. Togsverd-Bo K, Lerche C, Poulsen T, Wulf HC, HÃdersdal M,. Photodynamic therapy with topical methyl- and hexylaminolevulinate for prophylaxis and treatment of UV-induced SCC in hairless mice. Exp Dermatol 2010; 19: e166-e172.
27. Wulf HC, Pavel S, Stender I, Bakker-Wensveen CA,. Topical photodynamic therapy for prevention of new skin lesions in renal transplant recipients. Acta Derm Venereol 2006; 86: 25-28.
28. Apalla Z, Sotiriou E, Chovarda E, Lefaki I, Devliotou-Panagiotidou D, Ioannides D,. Skin cancer: preventive photodynamic therapy in patients with face and scalp cancerization. A randomized placebo-controlled study. Br J Dermatol 2010; 162: 171-175.
29. Steinbauer JM, Schreml S, Babilas P, et al. Topical photodynamic therapy with porphyrin precursors-assessment of treatment-associated pain in a retrospective study. Photochem Photobiol Sci 2009; 8: 1111-1116.
30. Halldin CB, Paoli J, Sandberg C, Gonzalez H, Wennberg AM,. Nerve blocks enable adequate pain relief during topical photodynamic therapy of field cancerization on the forehead and scalp. Br J Dermatol 2009; 160: 795-800.
31. Martin G,. Prospective, case-based assessment of sequential therapy with topical fluorouracil cream 0.5% and ALA-PDT for the treatment of actinic keratosis. J Drugs Dermatol 2011; 10: 372-378.